JPH0632728A - External preparation for skin - Google Patents

External preparation for skin

Info

Publication number
JPH0632728A
JPH0632728A JP22772692A JP22772692A JPH0632728A JP H0632728 A JPH0632728 A JP H0632728A JP 22772692 A JP22772692 A JP 22772692A JP 22772692 A JP22772692 A JP 22772692A JP H0632728 A JPH0632728 A JP H0632728A
Authority
JP
Japan
Prior art keywords
skin
external preparation
acid
present
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP22772692A
Other languages
Japanese (ja)
Other versions
JP2720256B2 (en
Inventor
Takeshi Yanagida
威 柳田
Okihiko Sakamoto
興彦 阪本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16865400&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0632728(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP22772692A priority Critical patent/JP2720256B2/en
Priority to PCT/JP1993/000968 priority patent/WO1994001083A1/en
Priority to ES93914996T priority patent/ES2191664T5/en
Priority to EP93914996A priority patent/EP0610511B2/en
Priority to DE69332818T priority patent/DE69332818T3/en
Priority to KR1019940700810A priority patent/KR100298009B1/en
Priority to AT93914996T priority patent/ATE235883T1/en
Publication of JPH0632728A publication Critical patent/JPH0632728A/en
Priority to US08/616,914 priority patent/US5686086A/en
Publication of JP2720256B2 publication Critical patent/JP2720256B2/en
Application granted granted Critical
Priority to US09/210,618 priority patent/US5962000A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

PURPOSE:To obtain an external preparation for skin having synergistically enhanced chapped skin-improving effects such as preventing and improving effects on change or disorder caused by aging or exposure to sunlight of skin, taking safety into consideration. CONSTITUTION:This external preparation for skin comprises 0.00001-5.0wt.%, preferably 0.0001-0.5wt.% vitamin A and 0.0001-5.0wt.% antiinflammatory medicine. Hydrocortisone, prednisolone, dexamethasone, betamethasone, triamcinolone, aspirin, mefenamic acid, flufenamic acid, indomethacin, ibuprofen, glycyrrhizic acid, azulene, camphor, thymol, allantoin, etc., may be cited as the antiinflammatory medicine.

Description

【発明の詳細な説明】Detailed Description of the Invention

【０００１】[0001]

【産業上の利用分野】本発明は皮膚外用剤に関し、さら
に詳しくはビタミンＡと抗炎症薬を含有することにより
ビタミンＡのもつ肌荒れ改善効果を相乗的に向上させ安
全性にも配慮した皮膚外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin, and more specifically, an external preparation for skin in which vitamin A and an anti-inflammatory agent are contained to synergistically improve the rough skin improving effect of vitamin A and also considering safety. Regarding agents.

【０００２】[0002]

【従来の技術】皮膚外用剤には種々の薬効成分が配合さ
れている。その中で皮膚の加齢、あるいは日光暴露等に
よる変化を予防、改善する効果も薬効の一つであり、こ
れらを目的とする化粧料等の皮膚外用剤が求められてき
た。2. Description of the Related Art Various external medicines have been incorporated into external preparations for skin. Among them, the effect of preventing and improving changes due to aging of the skin, exposure to sunlight, etc. is one of the medicinal effects, and external preparations for skin such as cosmetics have been sought for these purposes.

【０００３】こうした中で従来は、天然物から抽出した
各種原料、例えばタンパク質、多糖、抽出エキス、天然
高分子等がその使用効果が特徴的であるため皮膚外用剤
に配合されてきた。Under these circumstances, conventionally, various raw materials extracted from natural products, such as proteins, polysaccharides, extracted extracts, natural polymers and the like, have been conventionally incorporated into external skin preparations because of their characteristic use effects.

【０００４】近年、ビタミンＡおよびその誘導体の中か
ら選ばれる一種または二種以上を配合し、皮膚の加齢あ
るいは日光暴露による変化、あるいは障害を防止、改善
する方法が開陳されている。（特表昭６４−５００３５
５）[0004] In recent years, a method has been disclosed in which one or more selected from vitamin A and its derivatives are blended to prevent or improve changes caused by aging of the skin or exposure to sunlight, or disorders. (Special table Sho 64-50035
5)

【０００５】[0005]

【発明が解決しようとする課題】従来技術の問題点 しかしながら、その効果は十分ではなく、より優れた効
果のある薬効剤の開発が待望されていた。BRIEF Problem to be Solved] However the prior art problems, the effect is not sufficient, it had been desired to develop a medicinal agent that is more excellent effect.

【０００６】発明の目的 本発明は前記従来技術の問題点に鑑みなされたものであ
り、その目的は、皮膚の加齢あるいは日光暴露による変
化、あるいは障害に対する防止効果、改善効果等の肌荒
れ改善効果を十分発揮させる皮膚外用剤を提供すること
にある。OBJECTS OF THE INVENTION The present invention has been made in view of the above-mentioned problems of the prior art, and an object thereof is an effect of preventing and improving skin roughness such as changes due to aging of the skin or exposure to sunlight, or damage. An object is to provide an external preparation for skin that fully exerts the above effects.

【０００７】前記目的を達成するために、本発明者らは
安全性に優れた物質の中から、特に十分な肌荒れ改善効
果を発現させる物質を得るべく鋭意研究を重ねた結果、
ビタミンＡと共に抗炎症薬を配合することによって、こ
れら問題点を解決することを見出した。In order to achieve the above object, the inventors of the present invention have conducted extensive studies to obtain a substance that exhibits a sufficient effect of improving rough skin, from among substances having excellent safety.
It has been found that blending an anti-inflammatory drug with vitamin A solves these problems.

【０００８】本発明者らは上記知見に基いて本発明を完
成するに至った。The present inventors have completed the present invention based on the above findings.

【０００９】[0009]

【課題を解決するための手段】すなわち、本発明はビタ
ミンＡと抗炎症薬とを含有することを特微とする皮膚外
用剤を提供するものである。以下、本発明の構成につい
て詳述する。That is, the present invention provides an external preparation for skin which is characterized by containing vitamin A and an anti-inflammatory drug. Hereinafter, the configuration of the present invention will be described in detail.

【００１０】本発明に用いられるビタミンＡは別名をレ
チノールとも言い、通常、医療分野等で小児病、夜盲症
の治療や妊娠後の回復剤として利用されている。これら
の中でａｌｌ−ｔｒａｎｓ体もしくは１３−ｃｉｓ体を
使用することが好ましく、それらの混合物を使用しても
かまわない。Vitamin A used in the present invention is also known as retinol, and is usually used in the medical field and the like as a remedy for pediatric diseases, night blindness and after pregnancy. Of these, it is preferable to use all-trans isomers or 13-cis isomers, and a mixture thereof may be used.

【００１１】本発明の皮膚外用剤へのビタミンＡの配合
量については限定はしないが、ビタミンＡの肌への効果
を考えると０．００００１重量％〜５．０重量％が好ま
しく、０．０００１重量％〜０．５重量％がより好まし
い。The amount of vitamin A to be added to the external preparation for skin of the present invention is not limited, but considering the effect of vitamin A on the skin, it is preferably 0.00001% by weight to 5.0% by weight, and 0.0001% by weight. % To 0.5% by weight is more preferred.

【００１２】本発明に用いられる抗炎症薬の例を挙げる
と、ヒドロコルチゾン、酢酸ヒドロコルチゾン、プレド
ニゾロン、メチルプレドニゾロン、酢酸プレドニゾロ
ン、酢酸プロピオン酸プレドニゾロン、デキサメタゾ
ン、ベタメタゾン、トリアムシノロン、酪酸クロベタゾ
ン、プロピオン酸クロベタゾール、フルオシノリド、酢
酸デキサメタゾン、吉草酸ベタメタゾン、トリアムシノ
ロンアセトニド、アスピリン、サリチル酸、アセトアミ
ノフェン、サリチル酸メチル、サリチル酸グリコール、
メフェナム酸、フルフェナム酸、インドメタシン、ジク
ロフェナック、ケトプロフェン、イブプロフェン、フル
ルビプロフェン、フェンブフェン、ブフェキサマック、
ピロキシカム、オキシフェンブタゾン、メピリゾール、
イブプロフェンピコノール、クリダナク、フェニルブタ
ゾン、ナプロキセン、グリチルレチン、グリチルリチ
ン、グリチルレチン酸およびその塩やエステル、グリチ
ルレチン酸およびその塩やエステル、アズレン、カンフ
ル、チモール、アラントイン等が挙げられ、これらの中
から一種もしくは二種以上を任意に選択できる。Examples of the anti-inflammatory drug used in the present invention include hydrocortisone, hydrocortisone acetate, prednisolone, methylprednisolone acetate, prednisolone acetate, prednisolone propionate acetate, dexamethasone, betamethasone, triamcinolone, clobetasol butyrate propionate, fluocinolide, and Dexamethasone acetate, betamethasone valerate, triamcinolone acetonide, aspirin, salicylic acid, acetaminophen, methyl salicylate, glycol salicylate,
Mefenamic acid, flufenamic acid, indomethacin, diclofenac, ketoprofen, ibuprofen, flurbiprofen, fenbufen, bufexamac,
Piroxicam, oxyphenbutazone, mepyrizole,
Ibuprofen piconol, kridanak, phenylbutazone, naproxen, glycyrrhetin, glycyrrhizin, glycyrrhetinic acid and its salts and esters, glycyrrhetinic acid and its salts and esters, azulene, camphor, thymol, allantoin, etc. Two or more kinds can be arbitrarily selected.

【００１３】本発明で使用される抗炎症薬の配合量は、
特に限定されるものではないが皮膚外用剤全量中、０．
０００１〜５．０重量％である。０．０００１重量％未
満では本発明の効果である皮膚刺激性が低減しない。
５．０重量％を越えて配合してもそれ以上の効果は望め
ない。The amount of the anti-inflammatory drug used in the present invention is
Although not particularly limited, in the total amount of the external preparation for skin, 0.
It is 0001 to 5.0% by weight. If it is less than 0.0001% by weight, the skin irritation which is the effect of the present invention is not reduced.
Even if it exceeds 5.0% by weight, no further effect can be expected.

【００１４】本発明の皮膚外用剤は前記の必須成分に加
えて、必要に応じ、本発明の効果を損なわない範囲内
で、化粧料、医薬部外品、医薬品等に一般に用いられる
各種成分、水性成分、保湿剤、増粘剤、紫外線吸収剤、
防腐剤、酸化防止剤、香料、色剤、薬剤、生薬、等が配
合される。もちろんこれらは本発明の目的を損なわない
質的、量的条件下で使用されなければならない。In addition to the above-mentioned essential components, the external preparation for skin of the present invention may optionally contain various components generally used in cosmetics, quasi drugs, pharmaceuticals, etc. within a range that does not impair the effects of the present invention. Aqueous component, moisturizer, thickener, UV absorber,
An antiseptic, an antioxidant, a fragrance, a coloring agent, a drug, a crude drug, etc. are mixed. Of course, these must be used under qualitative and quantitative conditions that do not impair the object of the present invention.

【００１５】また本発明の皮膚外用剤の剤型は任意であ
り、例えば化粧水等の可溶化系、乳液、クリーム等の乳
化系あるいは軟膏、粉末分散系、水−油二層系、水−油
−粉末三層系等どのような剤型でもかまわない。Further, the dosage form of the external preparation for skin of the present invention is arbitrary, for example, a solubilizing system such as lotion, an emulsifying system such as emulsion or cream, or an ointment, a powder dispersion system, a water-oil two-layer system, water- Any formulation such as oil-powder three-layer system may be used.

【００１６】[0016]

【実施例】次に実施例および比較例をあげて、本発明を
具体的に明らかにする。尚、本発明はこれにより限定さ
れるものではない。配合量は重量％である。EXAMPLES Next, the present invention will be specifically described with reference to Examples and Comparative Examples. The present invention is not limited to this. The blending amount is% by weight.

【００１７】＜＜実施例１〜５＞＞下記組成のクリーム
を製造し、肌荒れ改善効果について検討した。尚、配合
した抗炎症剤は下記表１に記載したものを使用した。 重量％ （１）セトステアリルアルコール ３．５ （２）スクワラン ３０．０ （３）ミツロウ ３．０ （４）還元ラノリン ５．０ （５）エチルパラベン ０．３ （６）ポリオキシエチレン（５０モル）オレイルアルコールエーテル ２．０ （７）ステアリン酸モノグリセリド ２．０ （８）抗炎症剤 （表１に記載） ０．１ （９）香料 ０．０３ （１０）ビタミンＡ ０．０００１ （１１）グリセリン １５．０ （１２）精製水 残余 製法 （１）、（２）、（３）、（４）、（５）、（６）、
（７）、（８）、（９）、（１０）を加熱溶解し、７５
℃に保ったものを７５℃に加温した（１１）、（１２）
に撹拌しながら加える。ホモミキサーで撹拌乳化しなが
ら冷却してクリームを得た。<< Examples 1 to 5 >> A cream having the following composition was produced and the effect of improving rough skin was examined. The anti-inflammatory agents used were those listed in Table 1 below. Weight% (1) cetostearyl alcohol 3.5 (2) squalane 30.0 (3) beeswax 3.0 (4) reduced lanolin 5.0 (5) ethylparaben 0.3 (6) polyoxyethylene (50 mol ) Oleyl alcohol ether 2.0 (7) Stearic acid monoglyceride 2.0 (8) Anti-inflammatory agent (described in Table 1) 0.1 (9) Perfume 0.03 (10) Vitamin A 0.0001 (11) Glycerin 15.0 (12) Purified water Residual production method (1), (2), (3), (4), (5), (6),
(7), (8), (9) and (10) are heated and dissolved, and 75
What was kept at ℃ was heated to 75 ℃ (11), (12)
While stirring. The mixture was cooled with stirring with a homomixer to obtain a cream.

【００１８】＜＜比較例１＞＞実施例１の処方から抗炎
症薬を除いた以外は全て同じ処方。<< Comparative Example 1 >> All the same formulations except that the anti-inflammatory drug was removed from the formulation of Example 1.

【００１９】＜＜比較例２＞＞実施例１の処方からビタ
ミンＡを除いた以外は全て同じ処方。<< Comparative Example 2 >> All the same formulations except that vitamin A was omitted from the formulation of Example 1.

【００２０】[0020]

【表１】 [Table 1]

【００２１】＜肌荒れ改善試験方法＞乾癬様、肌荒れ様
の皮膚疾患を有する被験者１００名をパネルとして５群
に分け、１群（１群２０名）ごとに実施例１〜５及び比
較例１〜２のクリームを使用させた。すなわち実施例１
〜５のクリームを、パネルの左顔面へ１日２回ずつ塗布
し、比較例１と比較例２のクリームを右顔面に塗布さ
せ、３ケ月連続使用後、使用前に比べて使用後の全般改
善度を肉眼判定した。その結果を表２に示す。<Test method for rough skin improvement> 100 subjects having psoriasis-like and rough skin-like skin diseases were divided into 5 groups as a panel, and Examples 1 to 5 and Comparative Examples 1 to 1 for each group (20 persons per group). 2 creams were used. That is, Example 1
The creams of Nos. 5 to 5 are applied to the left face of the panel twice a day, and the creams of Comparative Example 1 and Comparative Example 2 are applied to the right face, and after 3 consecutive months of use, the general after use compared to before use The degree of improvement was visually judged. The results are shown in Table 2.

【００２２】[0022]

【表２】 [Table 2]

【００２３】表２の結果から明らかなように実施例１〜
５の本発明品は比較例１、比較例２のものに比べて相乗
的に優れた肌荒れ改善効果を有していることが判った。As is clear from the results of Table 2, Examples 1 to 1
It was found that the product of No. 5 of the present invention had a synergistically excellent effect of improving rough skin as compared with those of Comparative Examples 1 and 2.

【００２４】 実施例６ 化粧水 重量％ （１）ビタミンＡ ０．００００１ （２）ベタメタゾン ０．０１ （３）グリセリン １．０ （４）精製水 残余 （５）エタノール ７．０ （６）ポリオキシエチレン（５０モル）オレイルアルコールエーテル １．０ （７）メチルパラベン ０．０５ （８）オレイルアルコール １．０ （９）乳酸 ０．０１ （１０）乳酸ナトリウム ０．１ （１１）香料 ０．０１ （製法）精製水に（３）、（９）、（１０）を溶解す
る。別にエタノールに（１）、（２）、（６）、
（７）、（１１）を溶解し、これを前記の精製水に加え
て溶解し濾過し化粧水を得た。本発明の化粧水は、皮膚
改善効果に優れていた。Example 6 Skin Lotion Weight% (1) Vitamin A 0.00001 (2) Betamethasone 0.01 (3) Glycerin 1.0 (4) Purified Water Residual (5) Ethanol 7.0 (6) Polyoxy Ethylene (50 mol) oleyl alcohol ether 1.0 (7) Methylparaben 0.05 (8) Oleyl alcohol 1.0 (9) Lactic acid 0.01 (10) Sodium lactate 0.1 (11) Perfume 0.01 (Production method ) Dissolve (3), (9) and (10) in purified water. Separately in ethanol (1), (2), (6),
(7) and (11) were dissolved, and this was added to the above purified water to dissolve and filtered to obtain a lotion. The lotion of the present invention was excellent in the skin improving effect.

【００２５】 実施例７ パック 重量％ （１）酢酸デキサメタゾン ０．５ （２）ポリビニルアルコール １０．０ （３）プロピレングリコール ７．０ （４）エタノール １０．０ （５）ビタミンＡ ０．０１ （６）メチルパラベン ０．０５ （７）ＰＯＥ（６０モル）硬化ひまし油 ０．２ （８）香料 ０．０５ （９）精製水 残余 製法 （９）に（１）、（３）、（６）、（７）を加え撹拌溶
解する。次に（２）を加え加熱撹拌し、（９）を溶解し
た、（４）を加え撹拌溶解してパックを得た。本発明の
パックは、皮膚改善効果に優れていた。Example 7 Pack Weight% (1) Dexamethasone Acetate 0.5 (2) Polyvinyl Alcohol 10.0 (3) Propylene Glycol 7.0 (4) Ethanol 10.0 (5) Vitamin A 0.01 (6) ) Methylparaben 0.05 (7) POE (60 mol) hydrogenated castor oil 0.2 (8) Perfume 0.05 (9) Purified water Residual production method (1), (3), (6), (7) ) Is added and dissolved by stirring. Next, (2) was added and heated and stirred to dissolve (9). (4) was added and dissolved by stirring to obtain a pack. The pack of the present invention was excellent in the skin improving effect.

【００２６】 実施例８ 固型白粉 重量％ （１）ビタミンＡ ０．０００５ （２）タルク ８５．４ （３）ステアリン酸 ２．５ （４）スクワラン ３．５ （５）ソルビタンセスキオレイン酸エステル １．８ （６）トリエタノールアミン １．２ （７）ジクロフェナック ０．０１ （８）顔料 適量 （９）香料 適量 製法 タルク、顔料をニーダーで十分混合する。（粉末部）ト
リエタノールアミンを５０％相当量の精製水に加え７０
℃に保つ。（水相）香料を除く本発明の成分を混合し、
加熱溶解して７０℃に保つ。（油相）水相に油相を加え
ホモミキサーで均一に乳化し、これを粉末部に加えニー
ダーで練り併せた後、水分を蒸発させ粉砕機で処理す
る。さらにこれをよく掻き交ぜながら香料を均一に噴霧
し圧縮成形する。本発明の固型白粉は優れた肌荒れ改善
効果を示した。Example 8 Solid White Powder Weight% (1) Vitamin A 0.0005 (2) Talc 85.4 (3) Stearic Acid 2.5 (4) Squalane 3.5 (5) Sorbitan Sesquioleate 1 .8 (6) Triethanolamine 1.2 (7) Diclofenac 0.01 (8) Appropriate amount of pigment (9) Perfume suitable amount Producing method Talc and pigment are thoroughly mixed with a kneader. (Powder part) Add triethanolamine to 50% of purified water and add 70
Keep at ℃. (Aqueous phase) Mix the ingredients of the present invention except the fragrance,
Melt by heating and keep at 70 ° C. (Oil phase) The oil phase is added to the water phase and uniformly emulsified with a homomixer. This is added to the powder part and kneaded with a kneader, then water is evaporated and the mixture is processed with a grinder. Further, while thoroughly stirring this, the fragrance is uniformly sprayed and compression molded. The solid white powder of the present invention has an excellent effect of improving rough skin.

【００２７】 実施例９ 口紅 重量％ （１）ビタミンＡ ０．００００１ （２）マイクロクリスタリンワックス ３．０ （３）ミツロウ ３．０ （４）セレシンワックス ５．０ （５）流動パラフィン １９．０ （６）スクワラン ２０．０ （７）カルナバロウ ３．０ （８）キャンデリラロウ ３．０ （９）グリチルレチン酸ステアリル ５．０ （１０）調合色剤 ７．０ （１１）ジブチルヒドロキシトルエン ０．０５ （１２）香料 適量 （１３）ラノリン 残余 製法 常法により口紅を得た 本発明の口紅はくちびるのかさつきを防いだ。Example 9 Lipstick wt% (1) Vitamin A 0.00001 (2) Microcrystalline wax 3.0 (3) Beeswax 3.0 (4) Ceresin wax 5.0 (5) Liquid paraffin 19.0 ( 6) Squalane 20.0 (7) Carnauba wax 3.0 (8) Candelilla wax 3.0 (9) Stearyl glycyrrhetinate 5.0 (10) Coloring agent 7.0 (11) Dibutylhydroxytoluene 0.05 ( 12) Perfume proper amount (13) Lanolin Residual production method The lipstick of the present invention, which was obtained by a conventional method, prevented the lips from becoming bulky.

【００２８】 実施例１０ 乳液 重量％ （１）ビタミンＡ １．０ （２）酢酸ヒドロコルチゾン ０．０５ （３）エタノール ２．０ （４）グリセリン １０．０ （５）プロピレングリコール ３．０ （６）カルボキシビニルポリマー ０．３ （７）ＫＯＨ ０．１ （８）メチルパラベン ０．１ （９）セタノール ２．５ （１０）ワセリン ２．０ （１１）スクワラン １０．０ （１２）イソプロピルミリステート ５．０ （１３）グリセリルモノステアレート ２．０ （１４）ＰＯＥ（２５モル）セチルエーテル ２．０ （１５）精製水 残余 製法 常法により本発明の乳液を得た。本発明の乳液は肌荒れ
改善効果に優れていた。Example 10 Emulsion Weight% (1) Vitamin A 1.0 (2) Hydrocortisone Acetate 0.05 (3) Ethanol 2.0 (4) Glycerin 10.0 (5) Propylene Glycol 3.0 (6) Carboxyvinyl polymer 0.3 (7) KOH 0.1 (8) Methylparaben 0.1 (9) Cetanol 2.5 (10) Vaseline 2.0 (11) Squalane 10.0 (12) Isopropyl myristate 5.0 (13) Glyceryl monostearate 2.0 (14) POE (25 mol) cetyl ether 2.0 (15) Purified water Residual production method The emulsion of the present invention was obtained by a conventional method. The emulsion of the present invention was excellent in the effect of improving rough skin.

【００２９】 実施例１１ 乳液 重量％ （１）ビタミンＡ ０．３ （２）インドメタシン ０．３ （３）エタノール ５．０ （４）グリセリン ５．０ （５）プロピレングリコール ５．０ （６）カルボキシビニルポリマー ０．２ （７）ＫＯＨ ０．０６ （８）メチルパラベン ０．２ （９）ＰＯＥ（６０モル）硬化ひまし油 １．０ （１０）スクワラン ３．０ （１１）イソプロピルミリステート ３．０ （１２）精製水 残余 製法 常法により本発明の乳液を得た。本発明の乳液は肌荒れ
改善効果に優れていた。Example 11 Emulsion wt% (1) Vitamin A 0.3 (2) Indomethacin 0.3 (3) Ethanol 5.0 (4) Glycerin 5.0 (5) Propylene glycol 5.0 (6) Carboxy Vinyl polymer 0.2 (7) KOH 0.06 (8) Methylparaben 0.2 (9) POE (60 mol) hydrogenated castor oil 1.0 (10) Squalane 3.0 (11) Isopropyl myristate 3.0 (12) ) Purified water Residual production method The emulsion of the present invention was obtained by a conventional method. The emulsion of the present invention was excellent in the effect of improving rough skin.

【００３０】 実施例１２ ナイトクリーム 重量％ （１）スクワラン １０．０ （２）流動パラフィン １０．０ （３）ワセリン ３．０ （４）セチルオクタノエート １０．０ （５）ジブチルフタレート ５．０ （６）グリチルリチン酸ステアリル ０．１ （７）インドメタシン ０．２ （８）ブチルパラベン ０．２ （９）ジグリセリントリイソステアレート ２．０ （１０）ジグリセリンモノイソステアレート １．５ （１１）ビタミンＡ ０．１ （１２）グリセリン １０．０ （１３）プロピレングリコール ６．０ （１４）精製水 残余 製法 常法により本発明のナイトクリームを得た。本発明のナ
イトクリームは肌荒れ改善効果に優れていた。Example 12 Night Cream Weight% (1) Squalane 10.0 (2) Liquid Paraffin 10.0 (3) Vaseline 3.0 (4) Cetyl Octanoate 10.0 (5) Dibutylphthalate 5.0 (6) Stearyl glycyrrhizinate 0.1 (7) Indomethacin 0.2 (8) Butylparaben 0.2 (9) Diglycerin triisostearate 2.0 (10) Diglycerin monoisostearate 1.5 (11) ) Vitamin A 0.1 (12) Glycerin 10.0 (13) Propylene glycol 6.0 (14) Purified water Residual production method The night cream of the present invention was obtained by a conventional method. The night cream of the present invention was excellent in the effect of improving rough skin.

【００３１】[0031]

【発明の効果】本発明の皮膚外用剤は表膚障害を防止
し、皮膚の加齢あるいは日光暴露による変化、あるいは
障害を防止、改善する効果等の肌荒れ改善を相乗的に向
上させ安全性にも配慮した皮膚外用剤である。The external preparation for skin of the present invention synergistically improves the rough skin improvement such as the effect of preventing and improving epidermis disorders, preventing or ameliorating changes caused by aging of the skin or exposure to sunlight, or disorders. It is also an external skin preparation.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 7/00 Ｆ 9164−4Ｃ Ｗ 9164−4Ｃ 31/07 8413−4Ｃ 31/19 8413−4Ｃ 31/195 8413−4Ｃ 31/405 9360−4Ｃ 31/505 9360−4Ｃ 31/54 9360−4Ｃ 31/57 9360−4Ｃ 31/60 9360−4Ｃ 31/70 8314−4Ｃ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI Technical indication location A61K 7/00 F 9164-4C W 9164-4C 31/07 8413-4C 31/19 8413-4C 31 / 195 8413-4C 31/405 9360-4C 31/505 9360-4C 31/54 9360-4C 31/57 9360-4C 31/60 9360-4C 31/70 8314-4C

Claims (2)

【特許請求の範囲】[Claims] 【請求項１】ビタミンＡと抗炎症薬とを含有することを
特徴とする皮膚外用剤。1. An external preparation for skin, which comprises vitamin A and an anti-inflammatory drug. 【請求項２】抗炎症薬がヒドロコルチゾン、酢酸ヒドロ
コルチゾン、プレドニゾロン、メチルプレドニゾロン、
酢酸プレドニゾロン、酢酸プロピオン酸プレドニゾロ
ン、デキサメタゾン、ベタメタゾン、トリアムシノロ
ン、酪酸クロベタゾン、プロピオン酸クロベタゾール、
フルオシノリド、酢酸デキサメタゾン、吉草酸ベタメタ
ゾン、トリアムシノロンアセトニド、アスピリン、サリ
チル酸、アセトアミノフェン、サリチル酸メチル、サリ
チル酸グリコール、メフェナム酸、フルフェナム酸、イ
ンドメタシン、ジクロフェナック、ケトプロフェン、イ
ブプロフェン、フルルビプロフェン、フェンブフェン、
ブフェキサマック、ピロキシカム、オキシフェンブタゾ
ン、メピリゾール、イブプロフェンピコノール、クリダ
ナク、フェニルブタゾン、ナプロキセン、グリチルレチ
ン、グリチルリチン、グリチルレチン酸およびその塩や
エステル、グリチルレチン酸およびその塩やエステル、
アズレン、カンフル、チモール、アラントインの中から
選ばれる一種もしくは二種以上である請求項１記載の皮
膚外用剤。2. The anti-inflammatory drug is hydrocortisone, hydrocortisone acetate, prednisolone, methylprednisolone,
Prednisolone acetate, prednisolone acetate propionate, dexamethasone, betamethasone, triamcinolone, clobetasone butyrate, clobetasol propionate,
Fluocinolide, dexamethasone acetate, betamethasone valerate, triamcinolone acetonide, aspirin, salicylic acid, acetaminophen, methyl salicylate, glycol salicylate, mefenamic acid, flufenamic acid, indomethacin, diclofenac, ketoprofen, ibuprofen, flurbiprofen, fenbufen,
Bufexamac, piroxicam, oxyphenbutazone, mepyrizole, ibuprofen piconol, kridanak, phenylbutazone, naproxen, glycyrrhetin, glycyrrhizin, glycyrrhetinic acid and its salts and esters, glycyrrhetinic acid and its salts and esters,
The external preparation for skin according to claim 1, which is one kind or two or more kinds selected from azulene, camphor, thymol and allantoin.
JP22772692A 1992-07-13 1992-07-13 External preparation for skin Expired - Lifetime JP2720256B2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP22772692A JP2720256B2 (en) 1992-07-13 1992-07-13 External preparation for skin
AT93914996T ATE235883T1 (en) 1992-07-13 1993-07-13 COMPOSITION FOR DERMATOLOGICAL PREPARATION
ES93914996T ES2191664T5 (en) 1992-07-13 1993-07-13 COMPOSITION FOR DERMATOLOGICAL PREPARATION.
EP93914996A EP0610511B2 (en) 1992-07-13 1993-07-13 Composition for dermatologic preparation
DE69332818T DE69332818T3 (en) 1992-07-13 1993-07-13 COMPOSITION FOR DERMATOLOGICAL PREPARATION
KR1019940700810A KR100298009B1 (en) 1992-07-13 1993-07-13 Skin external composition
PCT/JP1993/000968 WO1994001083A1 (en) 1992-07-13 1993-07-13 Composition for dermatologic preparation
US08/616,914 US5686086A (en) 1992-07-13 1996-03-18 External skin treatment composition
US09/210,618 US5962000A (en) 1992-07-13 1998-12-14 External skin treatment composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22772692A JP2720256B2 (en) 1992-07-13 1992-07-13 External preparation for skin

Publications (2)

Publication Number Publication Date
JPH0632728A true JPH0632728A (en) 1994-02-08
JP2720256B2 JP2720256B2 (en) 1998-03-04

Family

ID=16865400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP22772692A Expired - Lifetime JP2720256B2 (en) 1992-07-13 1992-07-13 External preparation for skin

Country Status (1)

Country Link
JP (1) JP2720256B2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11124308A (en) * 1997-10-22 1999-05-11 Kao Corp Cosmetic
JP2002080338A (en) * 2000-06-20 2002-03-19 Shiseido Co Ltd Antiaging skin care preparation
JP2002179549A (en) * 2000-12-12 2002-06-26 Kishohin Kagaku Kaiho Kenkyusho:Kk Skin care preparation
JP2003505490A (en) * 1999-07-30 2003-02-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin protection composition
JP2003505489A (en) * 1999-07-30 2003-02-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin protection composition containing petroselinic acid
JP2003512412A (en) * 1999-10-22 2003-04-02 ユニリーバー・ナームローゼ・ベンノートシヤープ Cosmetic composition containing resveratrol and retinoid
JP2003516952A (en) * 1999-12-14 2003-05-20 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin conditioning cosmetic composition containing red yeast rice extract
JP2007519689A (en) * 2004-01-29 2007-07-19 ピエール ファーブル デルモ−コスメティック Topical composition combining sodium hyaluronate fragments and retinoids
WO2008041623A1 (en) 2006-09-29 2008-04-10 Shiseido Company Ltd. External preparation for skin and cleansing agent for skin
JP2008184446A (en) * 2007-01-31 2008-08-14 Taisho Pharmaceutical Co Ltd Adapalene-containing external preparation composition
JP2011524884A (en) * 2008-06-20 2011-09-08 アンバート ミレー イグナシオ Dermatological pharmaceutical composition for the treatment of dermatitis diseases such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations thereof
JP2011241228A (en) * 2011-08-23 2011-12-01 Kishohin Kagaku Kaiho Kenkyusho:Kk Skin preparation for external use
JP2017137356A (en) * 2010-11-08 2017-08-10 エピテック グループ エッセ．エッレ．エッレ． Pharmacological preparations for topical use comprising n-palmitoyl-vanillamide

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11124308A (en) * 1997-10-22 1999-05-11 Kao Corp Cosmetic
JP2003505489A (en) * 1999-07-30 2003-02-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin protection composition containing petroselinic acid
JP4896326B2 (en) * 1999-07-30 2012-03-14 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin protective composition containing petroceric acid
JP2003505490A (en) * 1999-07-30 2003-02-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin protection composition
JP4841778B2 (en) * 1999-10-22 2011-12-21 ユニリーバー・ナームローゼ・ベンノートシヤープ Cosmetic composition containing resveratrol and retinoid
JP2003512412A (en) * 1999-10-22 2003-04-02 ユニリーバー・ナームローゼ・ベンノートシヤープ Cosmetic composition containing resveratrol and retinoid
JP2003516952A (en) * 1999-12-14 2003-05-20 ユニリーバー・ナームローゼ・ベンノートシヤープ Skin conditioning cosmetic composition containing red yeast rice extract
JP2002080338A (en) * 2000-06-20 2002-03-19 Shiseido Co Ltd Antiaging skin care preparation
JP2002179549A (en) * 2000-12-12 2002-06-26 Kishohin Kagaku Kaiho Kenkyusho:Kk Skin care preparation
JP2007519689A (en) * 2004-01-29 2007-07-19 ピエール ファーブル デルモ−コスメティック Topical composition combining sodium hyaluronate fragments and retinoids
US8968751B2 (en) 2004-01-29 2015-03-03 Pierre Fabre Dermo Cosmetique Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology
WO2008041623A1 (en) 2006-09-29 2008-04-10 Shiseido Company Ltd. External preparation for skin and cleansing agent for skin
JP2008184446A (en) * 2007-01-31 2008-08-14 Taisho Pharmaceutical Co Ltd Adapalene-containing external preparation composition
JP2011524884A (en) * 2008-06-20 2011-09-08 アンバート ミレー イグナシオ Dermatological pharmaceutical composition for the treatment of dermatitis diseases such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations thereof
JP2017137356A (en) * 2010-11-08 2017-08-10 エピテック グループ エッセ．エッレ．エッレ． Pharmacological preparations for topical use comprising n-palmitoyl-vanillamide
JP2011241228A (en) * 2011-08-23 2011-12-01 Kishohin Kagaku Kaiho Kenkyusho:Kk Skin preparation for external use

Also Published As

Publication number Publication date
JP2720256B2 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
JP2720256B2 (en) External preparation for skin
JPH05262636A (en) Dermatic external preparation for body
JPH03220129A (en) Sebum suppressant
JP2764510B2 (en) Whitening cosmetics
WO1995019762A1 (en) Dermatologic composition
KR100298009B1 (en) Skin external composition
DK166429B1 (en) APPLICATION OF COJIC ACID OR COJIC ACID / BETA-CYCLODEXTRIN INJURY COMPLEX FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR THE PREVENTION OF ELASTOSIS
JPH01275511A (en) External drug for skin
JPH06305932A (en) Skin external agent
JPH11510824A (en) Cosmetic method for treatment and prevention of signs of skin aging
JP3434911B2 (en) External preparation for skin
JPH1036282A (en) Agent for suppressing breakage of mucopolysaccharide
EP2116237A1 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
JP3057207B2 (en) External preparation for skin
JP3018130B2 (en) External preparation for skin
WO2004009063A1 (en) TOPICAL ANTIINFLAMMATORY PREPARATIONS OF η-TERPINENE
JPH05331050A (en) Antiphlogistic and analgesic medicine for external use
JP2003335651A (en) Skin care preparation for external use
JPH0948732A (en) Activated oxygen scavenging agent and composition containing the same
JP2522803B2 (en) Cosmetics
JPH10203921A (en) Skin preparation for external use
JP2003342181A (en) Skin external preparation
JPH0517317A (en) Cosmetic and external preparation
JPS6360909A (en) Skin drug for external use
JP2003137798A (en) Skin care preparation

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 19971014

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081121

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091121

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101121

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101121

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111121

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111121

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121121

Year of fee payment: 15

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121121

Year of fee payment: 15